PHARMACOKINETICS OF VINCRISTINE SULFATE IN ADULT CANCER-PATIENTS

Authors:
  • VSVS SETHI
    VS SETHI
  • DJDV JACKSON
    DV JACKSON
  • DWDR WHITE
    DR WHITE
  • FRF RICHARDS
    F RICHARDS
  • JSJJ STUART
    JJ STUART
  • HMHB MUSS
    HB MUSS
  • MCMR COOPER
    MR COOPER
  • CSCL SPURR
    CL SPURR

  • 1 January 1981
    • journal article
    • research article
    • Vol. 41  (9) , 3551-3555
    • PMID:7260915
Abstract
Vincristine concentration in serum from 1 min to 72 h was measured by radioimmunoassay in 14 patients with cancers following i.v. bolus injection of vincristine sulfate at 0.45-1.30 mg/m2. The pharmacokinetic data were analyzed by a nonlinear least-square regression program NONLIN. A 3-compartmental open model fitted the raw data better than a 2-compartmental model. The mean half-lives of the triphasic decay curves .alpha., .beta. and .gamma. were 1.9, 19.2 and 1359 min (22.6 h), respectively. The apparent volume of the central compartment and the volume of distribution at steady-state (Vdss)/1.73 m2 body surface area were 4.1 and 167.6 l, respectively. The plasma clearance was 141.9 ml/min per 1.73 m2; the area under the concentration .times. time curve from 0 to .infin. (AUC0.infin.) for 2 mg vincristine was 21,689 nM.cntdot.min. Linear regression analysis of the data gave evidence for increasing plasma clearance at higher doses of vincristine. In patients with higher platelet counts, lower AUC0.infin. values were obtained, suggesting a possible interaction of vincristine with blood platelets. These results, a large Vdss, a long biological half-life and a low rate-limiting rate constant from compartment 3 to the central compartment (k31), indicate an avid tissue binding and a slow drug release from the body tissues which may account for drug-related neurotoxicity.